New research has validated the health benefits of Hofseth BioCare’s OmeGo - a nutraceutical ingredient which offers 21 omegas and fatty acids - supporting its reputation to restore respiratory health and rebalance the immune system.
The study, published in Biomedicines, aimed to assess the extent to which OmeGo could reduce lung inflammation in a standard animal model of induced asthma. The findings showed that OmeGo significantly reduced eosinophilic lung and systemic inflammation and lung remodelling (scarring).
OmeGo is enzymatically liberated from fresh Atlantic salmon and is a close proxy for consuming whole fish. It is minimally processed with low levels of oxidation and free fatty acids and contains all of the polyunsaturated acids found in whole fish, not just omega-3.
The latest findings underpin OmeGo’s position as one-of-a-kind innovation that offers superior inflammation-resolving, anti-oxidant and anti-allergic properties compared to traditional fish oil supplementation, including cod liver oil. They also point to the potential of OmeGo as a pragmatic and proactive route to attaining better health outcomes, including improved immune response and more robust respiratory health.
“Fish oil is heavily processed and concentrates on just one or two elements of whole fish, such as Omega-3. While important, Omega-3 makes up only a fraction of the fish and its full potential is, therefore, unfulfilled,” said Dr Crawford Currie, Head of Medical R&D at Hofseth BioCare.
This latest study strengthens the growing bank of evidence that OmeGo, derived from fresh, whole, minimally-processed salmon offers an extensive and varied health benefit profile, beyond nutrition
Currie continued: “OmeGo is different. Thanks to our gentle manufacturing process, the significant inflammation-resolving benefits and protective effects against allergies associated with high grade, fresh Atlantic salmon are preserved. Nothing added, nothing diminished, nothing taken away. OmeGo is the closest consumers can get to eating whole fish and these latest findings show its promise in helping the body resolve inflammation, rebalance the immune system and promote healthy ageing. This latest study strengthens the growing bank of evidence that OmeGo, derived from fresh, whole, minimally-processed salmon offers an extensive and varied health benefit profile, beyond nutrition.”
Like all ingredients in the HBC product portfolio, OmeGo is classified as a New Dietary Ingredient (NDI) by the US Food & Drug Administration (FDA). It has several unique US FDA Structure Function Claims, including helping to support cardiovascular health and to sustain a healthy oxidative balance, thanks to potent antioxidant properties not naturally present in processed fish oils.
A global leader in marine lipid and peptide research, Hofseth BioCare uses patent-protected hydrolysis technology to convert fresh sashimi-grade salmon by-products into nutritional ingredients for the enhancement of human health. Further studies are in the pipeline to assess the potential positive effects of OmeGo on gut health, COPD, and pollution-induced inflammation.